Which diseases is tocilizumab effective in treating?

Tocilizumab is a humanized monoclonal antibody targeting the interleukin-6 (IL-6) receptor. It is an innovative biological agent currently widely used in clinical practice for a variety of autoimmune and inflammatory diseases. With in-depth research on the role of IL-6 in human inflammatory response and immune regulation, the indications of tocilizumab have gradually expanded to include rheumatoid arthritis (RA) and giant cell arteritis (GCA) , systemic juvenile idiopathic arthritis (sJIA), interstitial lung disease, adult Still's disease, cytokine release syndrome (CRS), and severe inflammatory reactions caused by new coronavirus infection, its therapeutic effect has been recognized in international guidelines.

First of all, in the field of rheumatoid arthritis (RA), tocilizumab has long been established as part of the basic treatment plan. RA is a chronic inflammatory arthropathy caused by abnormal activation of the immune system, characterized by symmetrical facet joint swelling, pain, and limited mobility. IL-6, as a key cytokine involved in inflammation amplification, plays an important role in the pathogenesis of RA. Tocilizumab significantly reduces the levels of inflammatory factors by blocking the binding of IL-6 to its receptors, thereby relieving joint symptoms, reducing morning stiffness and delaying joint structural damage. Its efficacy is particularly significant for patients who have failed to respond to treatment with methotrexate or TNF-α inhibitors, and has shown better disease remission rates than traditional drugs in multiple international clinical trials.

Secondly, tocilizumab has also achieved significant breakthroughs in the treatment of giant cell arteritis (GCA). GCA is an immune disease mainly caused by inflammation of the temporal artery and other large arteries. It is common in people over 50 years old. It mainly manifests symptoms such as headache, visual impairment, and jaw pain. If not treated in time, it may lead to blindness or stroke. As the first biological drug approved by the FDA for the treatment of GCA, tocilizumab can effectively replace high-dose glucocorticoids, reduce steroid dependence, control disease recurrence, and improve patients' quality of life.

In lung diseases, tocilizumab has made important progress in recent years in research related to interstitial lung disease (ILD), especially ILD related to rheumatic diseases, such as pulmonary fibrosis caused by systemic sclerosis. Since IL-6 plays a key role in chronic inflammation and pulmonary fibrosis, tocilizumab is expected to slow down the decline of lung function and improve dyspnea by intervening in this pathway. Although formal indication approval for interstitial lung disease has not yet been obtained in all countries, its actual clinical use has been gradually explored, especially in patient groups managed jointly by rheumatology, immunology and respiratory departments.

In addition, in the new coronavirus (Tocilizumab has also shown wide application value in severe inflammatory reactions caused by COVID-19. After being infected with the new coronavirus, some patients will develop a "cytokine storm", in which the immune system is overactivated and produces a large amount of pro-inflammatory factors, leading to acute respiratory distress syndrome (ARDS) and multiple organ dysfunction. IL-6 levels significantly increase during this process, so tocilizumab is used to inhibit the IL-6 pathway, reduce lung inflammation, and reduce severe disease and mortality rates. The World Health Organization (WHO) has also included it as one of the recommended treatment options for patients with severe COVID-19. Although its efficacy needs to be comprehensively evaluated based on the disease course, oxygenation status, etc., it has undoubtedly expanded the treatment boundaries of tocilizumab.

Reference materials:https://www.drugs.com/mtm/tocilizumab.html